SAREPTA THERAPEUTICS, INC. Accretion (Amortization) of Discounts and Premiums, Investments
SAREPTA THERAPEUTICS, INC. (SRPT) reported Accretion (Amortization) of Discounts and Premiums, Investments of $2.29 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-10-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments · last filed 2018-10-31
- SAREPTA THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2018-09-30 was $2.29M, a 430.02% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2018-06-30 was $1.57M, a 880.63% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2018-03-31 was $1.26M, a 1159.00% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2017-12-31 was $195.00K, a 50.38% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for fiscal 2017 was $888.00K.
- SAREPTA THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for fiscal 2016 was -$80.00K.
- SAREPTA THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for fiscal 2015 was -$652.00K.
| Period end | Accretion (Amortization) of Discounts and Premiums, Investments 3 month | Accretion (Amortization) of Discounts and Premiums, Investments 6 month | Accretion (Amortization) of Discounts and Premiums, Investments 9 month | Accretion (Amortization) of Discounts and Premiums, Investments 9 month as first filed | Accretion (Amortization) of Discounts and Premiums, Investments 12 month |
|---|---|---|---|---|---|
| 2018-09-30 | $2.29M 10-Q · filed 2018-10-31 | $3.86M derived: sum of 2 quarters · filed 2018-10-31 | $5.12M 10-Q · filed 2018-10-31 | $5.32M derived: sum of 4 quarters · filed 2018-10-31 | |
| 2018-06-30 | $1.57M 10-Q · filed 2018-08-08 | $2.83M 10-Q · filed 2018-08-08 | $3.02M derived: sum of 3 quarters · filed 2018-08-08 | $3.46M derived: sum of 4 quarters · filed 2018-10-31 | |
| 2018-03-31 | $1.26M 10-Q · filed 2018-05-03 | $1.45M derived: sum of 2 quarters · filed 2018-05-03 | $1.89M derived: sum of 3 quarters · filed 2018-10-31 | $2.05M derived: sum of 4 quarters · filed 2018-10-31 | |
| 2017-12-31 | $195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $628.00K derived: sum of 2 quarters · filed 2018-10-31 | $788.00K derived: sum of 3 quarters · filed 2018-10-31 | $888.00K 10-K · filed 2018-03-01 | |
| 2017-09-30 | $433.00K 10-Q · filed 2018-10-31 | $593.00K derived: sum of 2 quarters · filed 2018-10-31 | $693.00K 10-Q · filed 2018-10-31 | $144.00K 10-Q · filed 2017-11-01 | $1.09M derived: sum of 4 quarters · filed 2018-10-31 |
| 2017-06-30 | $160.00K 10-Q · filed 2018-08-08 | $260.00K 10-Q · filed 2018-08-08 | $653.00K derived: sum of 3 quarters · filed 2018-08-08 | ||
| 2017-03-31 | $100.00K 10-Q · filed 2018-05-03 | $493.00K derived: sum of 2 quarters · filed 2018-05-03 | |||
| 2016-12-31 | $393.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$80.00K 10-K · filed 2018-03-01 | |||
| 2016-09-30 | -$473.00K 10-Q · filed 2017-11-01 | ||||
| 2015-12-31 | -$652.00K 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |